AI-generated summary
The authors report a randomized trial of 135 adults with center-involved diabetic macular edema and good vision, comparing a 670-nm light therapy eye patch with a placebo device over 4 months. They found no significant difference in change in central subfield thickness or visual acuity between groups, and concluded the treatment was not effective as given, though safe and well tolerated.
- Participants
- 135
- Who or what was studied
- Adults with center-involved diabetic macular edema and visual acuity 20/25 or better in the study eye, recruited from 23 clinical sites in the United States; median age 62 years, 37% women, 82% White.
- Wavelengths
- 670 nm
- Limits stated in the abstract
- The abstract does not describe a control group beyond placebo, and the findings apply to the specific device and dosing used in this study.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Confidence interval, Retina. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.